Laurent Gilardin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2017953/publications.pdf

Version: 2024-02-01

566801 433756 4,908 29 15 31 citations h-index g-index papers 33 33 33 9570 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	3.3	110
2	Autoantibodies neutralizing type I IFNs are present in \sim 4% of uninfected individuals over 70 years old and account for \sim 20% of COVID-19 deaths. Science Immunology, 2021, 6, .	5.6	357
3	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,749
4	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,983
5	Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity. Acta Oncol \tilde{A}^3 gica, 2020, 59, 484-489.	0.8	4
6	Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy. Cell Death and Disease, 2020, 11, 50.	2.7	30
7	Adjunct Immunotherapies for the Management of Severely III COVID-19 Patients. Cell Reports Medicine, 2020, 1, 100016.	3.3	102
8	Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?. Leukemia and Lymphoma, 2019, 60, 547-549.	0.6	3
9	Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. Journal of Allergy and Clinical Immunology, 2019, 144, 524-535.e8.	1.5	36
10	Ibrutinib and idelalisib in the management of CLLâ€associated autoimmune cytopenias: a study from the FILO group. American Journal of Hematology, 2019, 94, E183-E185.	2.0	12
11	Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2019, 23, 132-137.	0.6	19
12	Symptomatic muscular sarcoidosis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e452.	3.1	27
13	Complement C3 is a novel modulator of the anti-factor VIII immune response. Haematologica, 2018, 103, 351-360.	1.7	17
14	Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 2018, 118, 1729-1742.	1.8	24
15	Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO). Blood, 2018, 132, 3152-3152.	0.6	1
16	The ADAMTS13 ^{1239–1253} peptide is a dominant HLA-DR1-restricted CD4 ⁺ T-cell epitope. Haematologica, 2017, 102, 1833-1841.	1.7	14
17	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients. Journal of Immunology, 2016, 196, 4075-4081.	0.4	3
18	High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain, 2016, 139, 2131-2135.	3.7	202

#	Article	IF	CITATIONS
19	Wrist-worn accelerometer as innovative tool for longitudinal follow-up of idiopathic inflammatory myopathy patients: A pilot study. Neuromuscular Disorders, 2015, 25, S310.	0.3	3
20	Intravenous immunoglobulin as clinical immune-modulating therapy. Cmaj, 2015, 187, 257-264.	0.9	74
21	Identification of T Cell Epitope of ADAMTS13 in Thrombotic Thrombocytopenic Purpura Patients. Blood, 2015, 126, 106-106.	0.6	1
22	Interferonâ€Î± Inhibition by Intravenous Immunoglobulin Is Independent of Modulation of the Plasmacytoid Dendritic Cell Population in the Circulation: Comment on the Article by Wiedeman et al. Arthritis and Rheumatology, 2014, 66, 2308-2309.	2.9	2
23	Predictive immunogenicity of Refacto [®] <scp>AF</scp> . Haemophilia, 2014, 20, 486-492.	1.0	11
24	<i>In silico</i> calculated affinity of FVIIIâ€derived peptides for <scp>HLA</scp> class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia, 2014, 20, 176-184.	1.0	20
25	Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Scientific Reports, 2014, 4, 5672.	1.6	31
26	Peripheral <scp>T</scp> â€ell lymphoma in <scp>HIV</scp> â€infected patients: a study of 17 cases in the combination antiretroviral therapy era. British Journal of Haematology, 2013, 161, 843-851.	1.2	9
27	Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immuneâ€Mediated Inflammatory Diseases. Arthritis Care and Research, 2013, 65, 1504-1514.	1.5	43
28	IVIg Treatment Reduces Catalytic Antibody Titers of Renal Transplanted Patients. PLoS ONE, 2013, 8, e70731.	1.1	3
29	Pauci-immune Crescentic Glomerulonephritis Associated With ANCA of IgA Class. American Journal of Kidney Diseases, 2009, 53, 1063-1067.	2.1	6